Table 1.
Overall Participant Demographics and Baseline Characteristics
| Ubrogepant 100 mg Treatment Group (Representative of All Participants) (N = 30) | |
|---|---|
| Age,† years | |
| Mean (SD) | 33.2 (7.2) |
| Sex, n (%) | |
| Male | 10 (33.3) |
| Female | 20 (66.7) |
| Race, n (%) | |
| White | 19 (63.3) |
| Black or African‐American | 11 (36.7) |
| All other races | 0 |
| Ethnicity, n (%) | |
| Hispanic or Latino | 19 (63.3) |
| Not Hispanic or Latino | 11 (36.7) |
| Weight, kg | |
| Mean (SD) | 78.65 (12.13) |
| Height, cm | |
| Mean (SD) | 171.2 (10.35) |
| Body mass index, kg/m2 | |
| Mean (SD) | 26.75 (2.79) |
N = number of participants in the safety population.
Percentages are calculated as 100 × (n/N).
†
Age at screening.